Lexeo Therapeutics, Inc. Common Stock (LXEO) Stock

Lexeo Therapeutics, Inc. Common Stock (LXEO) is a Healthcare stock trading at $4.88 (as of 2026-08-21), with a market capitalization of $399.98M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

Understand Lexeo Therapeutics, Inc. Common Stock: how it makes money

Lexeo Therapeutics develops AAVrh10-based gene therapy candidates for hereditary and acquired diseases, including cardiomyopathies, and advances them through clinical trials (for example, LX2006 and LX2020 for Friedreich's ataxia and arrhythmogenic cardiomyopathy, respectively).

As a clinical-stage genetic medicine company, Lexeo's profit model depends on converting trial progress (dosing, patient enrollment, and efficacy signals like left ventricular mass index changes) into successful clinical readouts that enable future commercialization.

Business quality (Weak): Clinical progress is measurable through participant dosing and cardiology biomarkers, but near-term economics show no reported revenue and very large operating losses.

Bull case

Clear ongoing clinical dosing activity: Across two trials, Lexeo reports 17 participants dosed to date.
Efficacy signals tracked with an important cardiomyopathy biomarker: Reported left ventricular mass index mean improvement at 6 months is 18.0 percent, and at 12 months is 23.0 percent.
Multiple cardiomyopathy programs using the same AAVrh10 gene therapy platform: The company is developing several candidates, including LX2006, LX2020, LX2021, and LX2022.

Bear case

No reported revenue in the latest quarter: For the period ending 2026-03-31, revenue is shown as 0.0B.
Large operating losses: The operating margin is -1056.9 percent for 2026-03-31, reflecting substantial unprofitable operations.
Clinical outcomes remain uncertain and are dependent on future readouts: The dataset includes a tracked 'Primary Endpoint Topline Efficacy Readout Timing' value, implying key efficacy conclusions are not yet settled.

Valuation — source: SEC EDGAR (first-party)
Price	$4.88
Market Cap	$399.98M
Price / Book	1.70
Price / Sales	50.78
FCF Yield	-20.3%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$6.13M
Net Margin	-1630.7%
Revenue Growth (YoY)	-18.9%
EPS Growth (YoY)	-39.8%
FCF Growth (YoY)	21.2%

Financial Health — source: SEC EDGAR
Altman Z-Score	7.31 (safe)

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.7
Industry P/E (Pharmaceutical Products)	17.2

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	VANGUARD GROUP INC ($38.67M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	R. Nolan Townsend
Employees	75
Country	US
IPO Date	2023-11-03

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.